These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16633367)

  • 1. Measuring response in a post-RECIST world: from black and white to shades of grey.
    Michaelis LC; Ratain MJ
    Nat Rev Cancer; 2006 May; 6(5):409-14. PubMed ID: 16633367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
    Mazumdar M; Smith A; Schwartz LH
    J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New guidelines to evaluate the response to treatment "RECIST"].
    Sasaki T
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2179-84. PubMed ID: 11142160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General and statistical hierarchy of appropriate biologic endpoints.
    Sargent D
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
    Oxnard GR; Morris MJ; Hodi FS; Baker LH; Kris MG; Venook AP; Schwartz LH
    J Natl Cancer Inst; 2012 Oct; 104(20):1534-41. PubMed ID: 22927506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 8. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?
    Gehan EA; Tefft MC
    J Natl Cancer Inst; 2000 Feb; 92(3):179-81. PubMed ID: 10655425
    [No Abstract]   [Full Text] [Related]  

  • 9. Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?
    Sznol M
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1340-1. PubMed ID: 21268434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
    Simon RM; Steinberg SM; Hamilton M; Hildesheim A; Khleif S; Kwak LW; Mackall CL; Schlom J; Topalian SL; Berzofsky JA
    J Clin Oncol; 2001 Mar; 19(6):1848-54. PubMed ID: 11251017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.
    Harrington JA; Hernandez-Guerrero TC; Basu B
    Clin Oncol (R Coll Radiol); 2017 Dec; 29(12):770-777. PubMed ID: 29108786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
    Tuma RS
    J Natl Cancer Inst; 2006 Sep; 98(18):1272-4. PubMed ID: 16985244
    [No Abstract]   [Full Text] [Related]  

  • 13. Response assessment in clinical trials: implications for sarcoma clinical trial design.
    Jaffe CC
    Oncologist; 2008; 13 Suppl 2():14-8. PubMed ID: 18434633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents: clinical trial design.
    Tan AR; Swain SM
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):148-53. PubMed ID: 11706406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of nonrandomized trials in the evaluation of oncology drugs.
    Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
    Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.
    Markman M
    Curr Oncol Rep; 2009 Jan; 11(1):1-2. PubMed ID: 19080733
    [No Abstract]   [Full Text] [Related]  

  • 17. Measuring the clinical response. What does it mean?
    Therasse P
    Eur J Cancer; 2002 Sep; 38(14):1817-23. PubMed ID: 12204662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
    Pocard M; Soria JC; Aldaz-Carroll L; Bellet D
    J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954
    [No Abstract]   [Full Text] [Related]  

  • 19. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.